Myasthenia Gravis News - LARVOL Sigma

Myasthenia Gravis	Welcome, Profile Billing Logout

«1 2...8 9 10 11 121314 15 16 17 18...136 137 »

|||||||||| Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
Safety and efficacy of amifampridine in Lambert-Eaton Myasthenic Syndrome patients (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2858;
Amifampridine is an effective treatment in nonneoplastic LEMS patients. Treatment is well-tolerated and allows to lower dose of corticosteroids in the majority of patients.

|||||||||| Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) / argenx
Subcutaneous Efgartigimod PH20 Demonstrates Improvements in gMG Patients Regardless of Prior Administration Route (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2856;
Treatment is well-tolerated and allows to lower dose of corticosteroids in the majority of patients. Efgartigimod PH20 SC demonstrated comparable efficacy/safety in gMG participants previously treated with IV or SC formulations.

|||||||||| Comparison between IVIG and plasma exchange in the management of Myasthenia crisis (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2855;
Membrane based plasmapheresis reduced the duration of mechanical ventilation in MC compared to IVIg. Blood pressure monitoring is important during plasmapheresis.

|||||||||| Autoimmune diseases associated with neuromyelitis optica spectrum disorder: Population-based Registry data (B6) - Jul 2, 2024 - Abstract #EAN2024EAN_2851;
Blood pressure monitoring is important during plasmapheresis. NMOSD patients, especially AQP4-IgG seropositive ones, are rather frequently associated with wide spectrum of autoimmune diseases, including both organ-specific and systemic autoimmune disorders, and related pathogenic autoantibodies, in our defined cohort with European ethnical background.

|||||||||| Yescarta (axicabtagene ciloleucel) / Gilead
Severe myasthenia gravis and myositis overlap syndrome following CAR T cell therapy for B cell non-Hodgkin lymphoma. (A6) - Jul 2, 2024 - Abstract #EAN2024EAN_2658;
In our case, it occurred after CAR- T cells ceased to be detectable, coinciding with complete reconstitution of the B compartment. Further investigation of the mechanisms involved is warranted.

|||||||||| Deep peripheral blood mononuclear cell phenotyping aiming to separate early- and late-onset myasthenia gravis (A5) - Jul 2, 2024 - Abstract #EAN2024EAN_2649;
We have identified possible, biologically plausible, cell- surface biomarker candidates separating the two myasthenia patient subgroups, now being validated in an independent cohort. If confirmed, this may enable flow cytometry- based techniques to facilitate separation of the two MG subforms.

|||||||||| Zilbrysq (zilucoplan) / UCB
Long-term zilucoplan in generalised myasthenia gravis: 96-week follow-up interim analysis of RAISE-XT (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2620;
P2, P3
If confirmed, this may enable flow cytometry- based techniques to facilitate separation of the two MG subforms. In this interim analysis, zilucoplan demonstrated a favourable safety profile and improved MG- ADL, QMG and MSE responder rates, sustained up to 96weeks of treatment.

|||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Efgartigimod in generalized myasthenia gravis: a Chinese multicenter cohort study (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2619;
In this interim analysis, zilucoplan demonstrated a favourable safety profile and improved MG- ADL, QMG and MSE responder rates, sustained up to 96weeks of treatment. This multicenter clinical cohort study demonstrated that efgartigimod provides rapid disease control for gMG in realworld clinical practice.

|||||||||| Ultomiris (ravulizumab-cwvz) / AstraZeneca, Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Ravulizumab and Efgartigimod in myasthenia gravis: a real-world study (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2617;
Our data suggest that durable disease control in MG requires continuous administration of both fast- acting agents. Combination with more deeply intervening immunotherapies might restrain pathogenicity of AChR- Abs, improving long- term therapeutic efficacies.

|||||||||| Zilbrysq (zilucoplan) / UCB
Response over time with zilucoplan in generalised myasthenia gravis: Post hoc analysis of RAISE-XT 60-week follow up (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2616;
P2, P3
Most patients on zilucoplan were responders at Week 12 of the double- blind studies and, among them, responder rates remained high (>88%) throughout the OLE up to Week 60. Of patients who were non- responders at Week 12, approximately half became responders during the OLE, suggesting the benefit of continuing zilucoplan treatment beyond Week 12.

|||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2615;
FIGURE 1: NEDA- 3 status up to 5years of ofatumumab treatment. Tocilizumab is safe and effective in improving the MGADL score and reducing prednisone dose in refractory AChR- Ab+ gMG, suggesting tocilizumab has the potential to be a valuable therapeutic option for such patients.

|||||||||| Rituxan (rituximab) / Roche
Response to single rituximab can predict a better outcome of multi-cycle treatment in refractory myasthenia gravis (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2506;
Tocilizumab is safe and effective in improving the MGADL score and reducing prednisone dose in refractory AChR- Ab+ gMG, suggesting tocilizumab has the potential to be a valuable therapeutic option for such patients. The response to single low-dose rituximab can predict a better outcome of multi-cycle treatment in refractory MG.

|||||||||| Rituxan (rituximab) / Roche
A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2505;
The response to single low-dose rituximab can predict a better outcome of multi-cycle treatment in refractory MG. The nomogram achieved an optimal prediction of shortterm outcomes in patients treated with low-dose rituximab.

|||||||||| Zilbrysq (zilucoplan) / UCB
Early real-life experience of Zilucoplan in refractory generalized myasthenia gravis (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2504;
Also, Zilucoplan appears to be very easy to administer and has a favorable safety profile (2). Further data and longer observations are needed to confirm our data.

|||||||||| Steroid toxicity in adults with myasthenia gravis in the United States based on electronic health records (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2502;
Our results demonstrated steroid toxicity is significantly higher in patients with higher strength and repeated steroid usage. Patients experienced consistent elevation in steroid toxicity over time.

|||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Real-world reduction in oral corticosteroid utilization following efgartigimod initiation (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2501;
Background and Aims: Reducing or tapering oral corticosteroids (OCS, prednisone equivalent), a common treatment used in generalised myasthenia gravis (gMG), can alleviate risk related to long-term OCS usage. Early insights indicate that OCS usage was significantly reduced over 6 months post-efgartigimod initiation, while retaining MG-ADL response.

|||||||||| Soliris (eculizumab) / AstraZeneca
The safety and efficacy profile of Eculizumab in myasthenic crisis: A Prospective Case series (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2500;
Eculizumab was well-tolerated and effective in enhancing recovery and reducing disease activity in patients with MC. These findings support further large-scale prospective studies with extended follow-up to establish the safety and efficacy profile of eculizumab in a real-world setting.

|||||||||| Positive Predictive Value of Acetylcholine Receptor Autoantibody Testing by Radioimmunoprecipitation Assay (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2499;
Despite the high specificity of AChR-IgG testing by RIPA, the risk of false antibody positivity is not negligible in clinical practice (14% in this study). Caution is needed when low titer AChRIgG positivity (0.5-0.9 nmol/L) is detected in patients with symptoms that are nonspecific for MG.

|||||||||| Short-term and long-term prognoses in sub-very-late-onset and super-late-onset myasthenia gravis patients (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2498;
Caution is needed when low titer AChRIgG positivity (0.5-0.9 nmol/L) is detected in patients with symptoms that are nonspecific for MG. The patients with S-VLOMG had a better short-term prognosis compared to SLOMG patients, while their long-term prognosis remains similar.

|||||||||| Intensive care due to exacerbation of myasthenia gravis: risk factors and prognosis (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2496;
Our study shows an increased risk of intensive care for patients with LOMG or thymoma, occurring usually within six months from diagnosis. Special attention to early treatment choices should thus be given.

|||||||||| Rituxan (rituximab) / Roche
Rituximab alone is as effective as associated with steroids on naive patients with generalized Myasthenia Gravis (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2495;
Special attention to early treatment choices should thus be given. We suggest that RTX alone is as effective as RTX-CS in MG patients, indicating that avoiding steroids could reduce side effects, decrease rescue therapies, and not affect MG outcomes.

|||||||||| Adverse pregnancy outcomes in myasthenia gravis: A retrospective cohort study in a US health insurance claims database (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2494;
MG was associated with a greater burden of certain adverse perinatal outcomes, occurring in both mother and infant. Further research is needed to understand drivers of pregnancy outcomes in MG.

|||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2493;
EFG IV was well-tolerated across indications and doses studied. Most TEAEs were mild to moderate in severity and event rates did not increase with repeated treatment.

|||||||||| Association of the initiation timing of oral steroids with clinical prognosis in adult generalized myasthenia gravis (B7) - Jul 2, 2024 - Abstract #EAN2024EAN_2492;
Most TEAEs were mild to moderate in severity and event rates did not increase with repeated treatment. Adult GMG patients who received corticosteroid therapy within one year of the onset date show a higher rate of MSE and a lower rate of refractory status than the late-treatment GMG patients, indicating that treatment of corticosteroids starting within 12 months gave rise to a more favorable prognosis in GMG patients.

|||||||||| Frequency and severity of cardiovascular autonomic dysfunction in myasthenia gravis patients (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2270;

|||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Efgartigimod in immune?checkpoint inhibitor induced myasthenia gravis,myocarditis and myositis:a case report (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2214;

|||||||||| The Swedish Myasthenia Gravis registry: A nationwide, population-based high coverage registry (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2213;

|||||||||| Soliris (eculizumab) / AstraZeneca
Autoimmune thrombocytopenia in a patient with generalised Myasthenia Gravis in treatment with Eculizumab: a case-report (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2204;

|||||||||| OCULAR MYASTHENIA GRAVIS MIMICS (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2203;

|||||||||| Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Efgartigimod in AChR-Ab positive Myasthenia Gravis: a 2-year experience (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2200;

|||||||||| The Complex Connection Between Myasthenia Gravis and its association to Depression (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2192;

|||||||||| Soliris (eculizumab) / AstraZeneca, Ultomiris (ravulizumab-cwvz) / AstraZeneca
Generalized myasthenia gravis case series: Patients with myasthenia gravis switching from eculizumab to ravulizumab (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2190;

|||||||||| Rituxan (rituximab) / Roche
Rituximab in Acethylcholine Receptor Antibodiy-Positive Myasthenia Gravis: a Slovenian single centre experience (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2186;

|||||||||| Dropped head: Myasthenia gravis or Parkinsonism? The role of neurophysiology (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2183;

|||||||||| Ultomiris (ravulizumab-cwvz) / AstraZeneca
Impending Myasthenic Crisis successfully treated with Ravulizumab (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2179;

|||||||||| Prediction of refractory myasthenia gravis based on response to treatment within the first year from diagnosis (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2174;

|||||||||| Who should undergo thymectomy in non-thymomatous Myasthenia Gravis? Results from the Swedish Myasthenia Gravis Register (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2168;

|||||||||| Significance of Light Kappa Chains in Patients with Seronegative Myasthenia Gravis (MG) (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2161;

|||||||||| Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Roche
Eculizumab versus rituximab for refractory acetylcholine receptor-positive generalized myasthenia gravis (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2159;

|||||||||| Myasthenia Gravis Control: Evolution over Eight Years of Follow-up and Patient Characteristics (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2143;

|||||||||| Soliris (eculizumab) / AstraZeneca
Eculizumab in refractory generalized Myasthenia Gravis: a single center 1 year experience (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2142;

|||||||||| Ocular Myasthenia Gravis: Determining the Predictive Factors of Secondary Generalisation (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2140;

|||||||||| Soliris (eculizumab) / AstraZeneca
Different Posology Due to Synthetic Protein Allergy During Eculizumab Therapy in a Patient with Myasthenia Gravis (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2138;

|||||||||| Usefulness and feasibility of a self-monitoring diary for management and follow-up of patients with myasthenia gravis (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2126;

|||||||||| Lambert-Eaton myasthenic syndrome in a Sicilian cohort of patients: a clinico-neurophysiological and therapeutic study. (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_2122;

|||||||||| Myasthenia gravis and acute immune-mediated polyneuropathy. Simultaneous onset and diagnosis (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_1810;

|||||||||| Seasonal Variation in Myasthenia Gravis Incidence (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_1756;

|||||||||| MYASTHENIA GRAVIS AND SYSTEMIC LUPUS ERYTHEMATOSUS, A RARE BUT IMPORTANT ASSOCIATION REGARDING DIAGNOSIS AND TREATMENT (ePosters Virtual) - Jul 2, 2024 - Abstract #EAN2024EAN_1731;

|||||||||| Rystiggo (rozanolixizumab-noli) / UCB
Shine a light on RYSTIGGO (Product Theatre 2) - Jul 2, 2024 - Abstract #EAN2024EAN_1205;
Adult GMG patients who received corticosteroid therapy within one year of the onset date show a higher rate of MSE and a lower rate of refractory status than the late-treatment GMG patients, indicating that treatment of corticosteroids starting within 12 months gave rise to a more favorable prognosis in GMG patients. Sponsored by UCB

|||||||||| Rystiggo (rozanolixizumab-noli) / UCB
PT02 UCB: Shine a light on RYSTIGGO (Product Theatre 2) - Jul 2, 2024 - Abstract #EAN2024EAN_1204;
Sponsored by UCB Sponsored by UCB



	Diseases Companies Products Productz Mechanisms of Action Sites